Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Viracta Therapeutics Announced First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting; Said Cash, Cash Equivalents, And Investments Of Over $90M At Year-end 2022 Provide Anticipated Runway Into Late 2024

By Charles Gross
January 8, 2:11 PM
Viracta Therapeutics, Inc. (Nasdaq: VIRX) today announced new clinical data from the Phase 1b/2 trial of Nana-val in patients with EBV+ R/M NPC and other EBV+ solid tumors and outlined its key 2023 clinical objectives.

VIRX

Read More
1 minute read

Annexon Announced Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications; Said Well-Capitalized with Operating Runway into 2025

By Charles Gross
January 8, 12:22 PM
Annexon, Inc. (Nasdaq: ANNX) today reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of the body, brain and eye.

ANNX

Read More
1 minute read

Merus Announced Based On The Company’s Current Operating Plan, Existing Cash, Cash Equivalents And Marketable Securities, Expected To Fund Merus’ Operations Into Second Half 2025

By Charles Gross
January 8, 12:18 PM
Merus N.V. (Nasdaq: MRUS) today provided its 2023 outlook. - As of year-end 2022, more than 150 patients with NRG1 gene fusion positive ("NRG1+") cancer have been treated with zenocutuzumab ("Zeno") monotherapy - Petosemtamab clinical update planned for first half of 2023

MRUS

Read More
1 minute read

BioMarin Announced Stable and Durable Annualized Bleed Control for ROCTAVIAN in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; Said 92% of Patients off Prophylaxis at the End of Year 3

By Charles Gross
January 8, 12:16 PM
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from more than three years of follow up from its ongoing global Phase 3 GENEr8-1 study of ROCTAVIANTM (valoctocogene roxaparvovec), an investigational one-time gene therapy for the treatment of adults with severe hemophilia A.

BMRN